Patents by Inventor Daniel S. Kohane
Daniel S. Kohane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9168389Abstract: Systems and methods for the activation of species and/or the delivery of species to a target environment using harmonic generation materials are generally described.Type: GrantFiled: February 20, 2013Date of Patent: October 27, 2015Assignees: Massachusetts Institute of Technology, Children's Medical Center CorporationInventors: Robert S. Langer, Daniel S. Kohane, Aoune Barhoumi
-
Patent number: 9114009Abstract: Electrically conductive nanowires incorporated within scaffolds enhance tissue growth, bridge the electrically resistant pore walls and markedly improve electrical communication between adjacent cardiac cell bundles. Integration of conducting nanowires within 3D scaffolds should improve the therapeutic value of cardiac patches. Examples demonstrate efficacy of gold nanowires in alginate matrices seeded with cardiomyocytes.Type: GrantFiled: December 28, 2011Date of Patent: August 25, 2015Assignees: Children's Medical Center Corporation, Massachusetts Institute of TechnologyInventors: Tal Dvir, Daniel S. Kohane, Robert S. Langer, Brian Timko
-
Publication number: 20150132312Abstract: The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject. Previous techniques for removal of biological materials from blood, such as hemodialysis and plasmapheresis, were generally non-specific (i.e., they removed a multitude of proteins/toxins from the blood). By contrast, novel methods and devices described herein are capable of removing specific or single substances such as proteins from biological fluids such as blood in a specific manner. Such highly specific protein removal has a broad array of clinical applications, including treatment of inflammatory conditions and autoimmune diseases.Type: ApplicationFiled: March 14, 2013Publication date: May 14, 2015Applicant: Children's Medical Center CorporationInventors: James B. McAlvin, Boaz Mizrahi, Daniel S. Kohane, Ryan G. Wylie
-
Publication number: 20150079159Abstract: A dosing regimen for formulations that contain a therapeutic dosage of a site 1 sodium channel blocker, where the dosing regimen provides a prolonged nerve block and is in an effective amount to delay the onset of neuropathic pain, such as hyperalgesia and/or allodynia, for at least one week, and preferably longer at the site, and preferably the region (e.g. entire limb), where the nerve block was applied. The site 1 sodium channel blocker is preferably saxitoxin (STX), preferably in combination with a corticosteroid, preferably dexamethasone. In a preferred embodiment, liposomes are included in the formulation as a controlled release system, producing prolonged duration of block without systemic toxicity. As demonstrated by the examples, encapsulating STX in a controlled release system, such as liposomes, preferably also including a corticosteroid, and administering in suitable dosing regimen to achieve a prolonged nerve block without systemic toxicity, delays the onset of hyperalgesia.Type: ApplicationFiled: April 23, 2013Publication date: March 19, 2015Inventors: Sahadev Aramanethalgur Shankarappa, Daniel S. Kohane
-
Patent number: 8975268Abstract: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.Type: GrantFiled: July 15, 2014Date of Patent: March 10, 2015Assignee: The Children's Medical Center CorporationInventors: Charles Berde, Daniel S. Kohane
-
Patent number: 8975281Abstract: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.Type: GrantFiled: July 15, 2014Date of Patent: March 10, 2015Assignee: The Children's Medical Center CorporationInventors: Charles Berde, Daniel S. Kohane
-
Patent number: 8912304Abstract: The present invention provides inventive polyol-based polymers, materials, pharmaceutical compositions, and methods of making and using the inventive polymers and materials. In certain aspects of the invention, an inventive polymer corresponds to a polymer depicted below. Exemplary inventive polymers includes those prepared using polyol units (e.g., xylitol, mannitol, sorbitol, or maltitol) condensed with polycarboxylic acid units (e.g., citric acid, glutaric acid, or sebacic acid). The inventive polymers may be further derivatized or modified. For example, the polymer may be made photocrosslinkable by adding methacrylate moieties to the polymer.Type: GrantFiled: May 16, 2008Date of Patent: December 16, 2014Assignee: Massachusetts Institute of TechnologyInventors: Joost P. Bruggeman, Christiaan Nijst, Daniel S. Kohane, Robert S. Langer
-
Publication number: 20140329861Abstract: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.Type: ApplicationFiled: July 15, 2014Publication date: November 6, 2014Inventors: Charles Berde, Daniel S. Kohane
-
Publication number: 20140329841Abstract: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.Type: ApplicationFiled: July 15, 2014Publication date: November 6, 2014Inventors: Charles Berde, Daniel S. Kohane
-
Publication number: 20140288103Abstract: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.Type: ApplicationFiled: March 17, 2014Publication date: September 25, 2014Applicant: The Children's Medical Center CorporationInventors: Charles Berde, Daniel S. Kohane
-
Patent number: 8822410Abstract: The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration enhancer which increases the flux of a therapeutic agent (e.g., antibiotic) across the tympanic membrane. Such compositions are particularly useful in the treatment of otitis media. Additionally, the composition may include a sustained release agents that, in some embodiments form sustained release reservoirs, in situ, once administered to a patient.Type: GrantFiled: May 19, 2009Date of Patent: September 2, 2014Assignees: Children's Medical Center Corporation, Massachusetts Institute of TechnologyInventors: Emmanuel John Simons, Todd R. Hoare, Daniel S. Kohane, Robert S. Langer
-
Publication number: 20140234938Abstract: Systems and methods for the activation of species and/or the delivery of species to a target environment using harmonic generation materials are generally described.Type: ApplicationFiled: February 20, 2013Publication date: August 21, 2014Applicants: Children's Medical Center Corporation, Massachusetts Institute of TechnologyInventors: Robert S. Langer, Daniel S. Kohane, Aoune Barhoumi
-
Publication number: 20140212335Abstract: Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn2+ or Cu2+, to form, e.g., bis-Zn-DPA or bis-Cu-DPA, which can bind to the bacterial contaminants. The nanoparticles can be included in compositions for use in methods and systems to separate bacterial contaminants from liquids, such as liquids, such as blood, e.g., whole or diluted blood, buffer solutions, albumin solutions, beverages for human and/or animal consumption, e.g., drinking water, liquid medications for humans and/or animals, or other liquids.Type: ApplicationFiled: January 29, 2014Publication date: July 31, 2014Applicants: Massachusetts Institute of Technology, Children's Medical Center CorporationInventors: Jung-Jae Lee, Kyung Jae Jeong, Daniel S. Kohane
-
Publication number: 20140105960Abstract: Provided herein are hydrogels and hydrogel-forming compositions that are useful for, among others, tissue regeneration in vivo. Methods for generating such hydrogels, for example, from such hydrogel-forming compositions are also provided herein. Therapeutic methods employing hydrogels and hydrogel-forming composition, for example, for restoration of tissue perfusion in the context of acute ischemia, are also provided. The disclosure also describes kits comprising components useful for generating hydrogels as described herein.Type: ApplicationFiled: October 9, 2013Publication date: April 17, 2014Applicants: Children's Medical Center Corporation, Massachusetts Institute of TechnologyInventors: JANETA ZOLDAN, Robert S. Langer, Daniel S. Kohane, Daniel Griffith Anderson, Akihiko Kusanagi, Hila Epstein-Barash, Beata Chertok
-
Publication number: 20140080913Abstract: Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is provided by selecting the concentration of the local anesthetic and the permeation enhancer to provide selective permeability of the sensory and motor neurons to the enhancer.Type: ApplicationFiled: November 21, 2013Publication date: March 20, 2014Applicants: Massachusetts Institute of Technology, The Children's Medical Center CorporationInventors: Daniel S. Kohane, Itay Sagie
-
Publication number: 20140080841Abstract: Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and nonionic surfactants, were co-injected with tetrodotoxin (TTX) or bupivacaine at the sciatic nerve of Sprague-Dawley rats. All enhancers produced marked concentration-dependent improvements in the frequency and duration of block with TTX but not bupivacaine. An in vitro toxicity assay showed a wide range of CPE myotoxicity, but in vivo histological assessment showed no signs of muscle or nerve damage at concentrations of CPEs that produced a half-maximal increase in the duration of block of TTX. There was no systematic relationship between the enhancers' charge or hydrophobicity and their enhancement of block duration or potency.Type: ApplicationFiled: November 21, 2013Publication date: March 20, 2014Applicants: Massachusetts Institute of Technology, The Children's Medical Center CorporationInventors: Daniel S. Kohane, Itay Sagie, Emmanuel J. Simons
-
Publication number: 20140074253Abstract: The present invention generally relates to nanoscale wires and tissue engineering. In various embodiments, cell scaffolds for growing cells or tissues can be formed that include nanoscale wires that can be connected to electronic circuits extending externally of the cell scaffold. The nanoscale wires may form an integral part of cells or tissues grown from the cell scaffold, and can even be determined or controlled, e.g., using various electronic circuits. This approach allows for the creation of fundamentally new types of functionalized cells and tissues, due to the high degree of electronic control offered by the nanoscale wires and electronic circuits. Accordingly, such cell scaffolds can be used to grow cells or tissues which can be determined and/or controlled at very high resolutions, due to the presence of the nanoscale wires, and such cell scaffolds will find use in a wide variety of novel applications, including applications in tissue engineering, prosthetics, pacemakers, implants, or the like.Type: ApplicationFiled: September 4, 2013Publication date: March 13, 2014Applicants: President and Fellows of Harvard College, Children's Medical Center Corporation, Massachusetts Institute of TechnologyInventors: Charles M. Lieber, Jia Liu, Bozhi Tian, Tal Dvir, Robert S. Langer, Daniel S. Kohane
-
Publication number: 20140058069Abstract: The present invention generally relates to particles, including microgel particles, for purifying proteins and other species. In one aspect, the particles comprise a metal-chelating moiety, which may be distributed substantially evenly throughout the particle in certain embodiments. In some cases, the particles may be porous, and in some embodiments, the particles may be made sufficiently small, for example, in order to form a microgel containing the particles. Such particles may be useful, for example, in binding metal ions (for example, nickel ions) using the metal-chelating moieties. In some embodiments, such particles may also be used to bind certain analytes (for example, proteins) containing tags which attract metal ions, for example, histidine tags. Accordingly, in certain embodiments, the particles may be used for binding or trapping proteins.Type: ApplicationFiled: February 22, 2012Publication date: February 27, 2014Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Boaz Mizrahi, Daniel S. Kohane
-
Patent number: 8658699Abstract: Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and nonionic surfactants, were co-injected with tetrodotoxin (TTX) or bupivacaine at the sciatic nerve of Sprague-Dawley rats. All enhancers produced marked concentration-dependent improvements in the frequency and duration of block with TTX but not bupivacaine. An in vitro toxicity assay showed a wide range of CPE myotoxicity, but in vivo histological assessment showed no signs of muscle or nerve damage at concentrations of CPEs that produced a half-maximal increase in the duration of block of TTX. There was no systematic relationship between the enhancers' charge or hydrophobicity and their enhancement of block duration or potency.Type: GrantFiled: May 19, 2009Date of Patent: February 25, 2014Assignees: Massachusetts Institute of Technology, Children's Medical Center CorporationInventors: Daniel S. Kohane, Itay Sagie, Emmanuel J. Simons
-
Publication number: 20140030277Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.Type: ApplicationFiled: September 26, 2013Publication date: January 30, 2014Applicants: Whitehead Institute, The General Hospital Corporation d/b/a Massachusetts General Hospital, Boston University, Massachusetts Institute of TechnologyInventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Daniel S. Kohane, Jason E. Fuller, Robert S. Langer